The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 2, 1999, Pages 31-38

  Humphrey, P P A ^a   Bountra, C ^b   Clayton, N ^b   Kozlowski, K ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; CARBOLINE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

CONFERENCE PAPER; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; INTESTINE ABSORPTION; INTESTINE MOTILITY; IRRITABLE COLON; PAIN THRESHOLD; PRIORITY JOURNAL; SENSORY NERVE; ANIMAL; INTESTINE; PHYSIOLOGY; REVIEW;

ANIMALS; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; HUMANS; INTESTINES; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032919392     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (70)

1. Gershon MD. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 15-30
2. Bülbring E, Crema A. The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J Physiol 1959; 146: 18-28.
3. Cubeddu LX, Hoffmann IS. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics. J Clin Pharm 1993; 33: 691-7.
4. Racke K, Reimann A, Schworer H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behav Brain Res 1996; 73: 83-7.
5. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 1986; 25: 563-76.
6. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203.
7. Martin GR. 5-Hydroxytryptamine receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification (International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification). IUPHAR Media: London, 1998: 167-85.
8. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharm Chemother 1957; 12: 323-8.
9. Humphrey PPA, Barnard EA, International Union of Pharmacology. XIX. The IUPHAR Receptor code: a proposal for an alphanumeric classification system. Pharmacol Rev 1998; 50: 271-7.
10. Dalton DW, Feniuk W, Humphrey PPA. An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats. J Auton Pharmacol 1986; 6: 219-28.
11. 3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746-8.
12. 3 receptors. Med Res Rev 1990; 10: 441-75.
13. 3 receptors. Ann NY Acad Sci 1990; 600: 194-202.
14. 3 receptor antagonists. Pharmacol Toxicol 1992; 70: 157-62.
15. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986; 88: 497-9.
16. Tyers MB, Bunce KT, Humphrey PPA. Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol 1989; 25: S15-9.
17. Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992; 19: 1-8.
18. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991; 41: 574-95.
19. Herrstedt J. Development of antiemetic therapy in cancer patients. Acta Oncol 1995; 34: 637-40.
20. Roua F, Ciccarese G, Palladino MA, De Angelis V. Prevention of radiotherapy-induced emesis. Tumori 1998; 84: 274-8.
21. 3 recognition sites on vagal afferent terminals in the brainstem of the ferret. Neuroscience 1990; 38: 667-73.
22. 3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27: 147-57.
23. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharm Ther 1993; 7: 175-80.
24. 3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995; 114: 558-62.
25. 3 receptor antagonists on the depressor response to colorectal distension in the anaesthetised rat. Br J Pharmacol 1994; 112: 101P.
26. Moss HE, Sanger GJ. The effects of granisetron. ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990; 100: 497-501.
27. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-89.
28. 3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motility 1999; II: in press.
29. Gebhart GF. Visceral nociception: consequences, modulation and the future. Eur J Anaesthesiol 1995; 10 (Suppl.): 24-7.
30. Bernstein CN, Niazi N, Robert M, et al. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996; 66: 151-61.
31. Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterol 1997; 112: 55-63.
32. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 42-6.
33. Kilbinger H, Pfeuffer-Friederich I. Two types of receptors for 5-hydroxytryptamine on the cholinergic nerves of the guinea-pig myenteric plexus. Br J Pharmacol 1985; 85: 529-39.
34. Drakontides AB, Gershon MD. 5-hydroxytryptamine receptors in the mouse duodenum. Br J Pharmacol 1968; 33: 480-92.
35. 3 receptor mediated release of an inhibitory transmitter in guinea-pig isolated ileum. Br J Pharmacol 1987; 91: 359P.
36. 3 receptor agonist induces neurally mediated chloride transport in rat distal colon. J Surg Res 1993; 55: 55-9.
37. Franks CM, Hardcastle J, Hardcastle PT. Neural involvement in 5-hydroxytryptamine-induced net electrogenic ion secretion in the rat intestine in vivo. J Pharm Pharmacol 1996; 48: 411-6.
38. Hardcastle J, Hardcastle PT. 5-hydroxytryptamine-induced secretion by rat jejunum in vitro involves several 5-hydroxytryptamine receptor subtypes. J Pharm Pharmacol 1998; 50: 539-17.
39. Mourad FH, O'Donnell LJ, Dias JA, et al. Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut 1995; 37: 340-5.
40. 3 receptor antagonist ICS 205-930. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 339: 704-5.
41. Lamers CB. Closing remarks. Ondansetron: effects on gastrointestinal motility. Scand J Gastroenterol 1991; 188(Suppl): 124-6.
42. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996; 52: 773-94.
43. Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 1988; 450: 153-69.
44. Scott CM, Grundy D, Boissonade FM, Bountra C. Alosetron inhibits the colorectal distension-evoked depressor response and spinal c-fos expression in the anaesthetised rat. Gastroenterol 1997; 112: A822 (Abstract).
45. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 9: 1171-8.
46. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron. (GR1990; 38032F): a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharm Ther 1990; 4: 139-44.
47. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595-9.
48. 4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol 1996; 271: G849-57.
49. 4 serotonin receptors inhibits colonic functions in conscious rats and mice. J Pharm Exp Ther 1997; 281: 284-90.
50. 3 receptor antagonist, on stress-induced defecation. Eur J Pharmacol 1993; 250: 303-10.
51. 3 receptor antagonist slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477-80.
52. Forster JM, Houghton LA, Whorwell PJ. Alosetron shows colonic transit in patients with irritable bowel syndrome (IBS). Gastroenterol 1997; 112: A732 (Abstract).
53. 3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterol 1998; 114: A812 (Abstract).
54. 3 receptor antagonist. Drugs Future 1992; 17: 660-4.
55. 3 receptors. Br J Pharmacol 1991; 104: 259P.
56. Paton WDM, Rang HP. A kinetic approach to the mechanism of drug action. Adv Drug Res 1966; 3: 57-80.
57. Bond RA, Ornstein AG, Clarke DE. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J Pharmacol Exp Ther 1989; 249: 401-10.
58. 3 receptor antagonist. Br J Clin Pharmacol 1992; 33: 546P.
59. Costall B, Domeney AM, Kelly ME, Naylor RJ. Influence of 5-HT on cognitive performance. In: Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM, Coote JH eds. Serotonin, CNS Receptors and Brain Function. Oxford: Pergamon Press, 1992; 85: 147-64.
60. 3 receptor antagonist GR68755 on a scopolamine-induced cognitive deficit in healthy subjects. Br J Clin Pharmacol 1992; 33: 546P.
61. Ness TJ, Gebhart GF. Differential effects of morphine and clonidine upon visceral and cutaneous nociceptive transmission in the rat. J Neurophysiol 1989; 62: 220-30.
62. Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. Naunyn-Schmiedeberg's Arch Pharmacol 1982; 321: 116-22.
63. Clark SJ, Smith TW. Opiate-induced inhibition of the visceral distension reflex by peripheral and central mechanisms. Naunyn-Schmiedeberg's Arch Pharmacol 1985; 330: 179-83.
64. Scott RB, Diamant SC, Gall DG. Motility effects of intestinal anaphylaxis in the rat. Am J Physiol 1988; 255: G505-11.
65. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmentai perfusion study. Aliment Pharmacol Ther 1997; 11: 1109-14.
66. 3 antagonist alosetron, in patients with carcinoid diarrhoea. Gut 1998; 42: 628-34.
67. Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-7.
68. Bardhan K, Bodemar G, Geldof H, Schutz E, Snell C, Darekar B. Effect of alosetron on colonic sensitivity in patients with irritable bowel syndrome (IBS). Gastroenterol 1996; 110: A630 (Abstract).
69. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
70. Gunput MD. Clinical pharmacology of alosetron. Aliment Pharm Ther 1999; 13 (Suppl. 2): 69-76.